Hims & Hers launching GLP-1 tracker, Yahoo Finance reports

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide their location, and say which brand of GLP-1 drug they are not able to find, Yahoo Finance’s Anjalee Khemlani reports. The data will be aggregated and regularly published by Hims in order to provide proof to the FDA that the shortages of the branded drugs haven’t ended, co-founder and CEO Andrew Dudum said in an interview. “We shared, as of a week ago, north of 80,000 people on our platform … are not able to get access to these medicines and reporting shortage. And that’s really only accelerating. Last week, we had more than 2,000 people in one day,” Dudum said.